41 results about "Pharmaceutics" patented technology

The invention discloses a chondroitin sulfate modified dihydromyricetin solid lipid nanoparticle, and belongs to the field of pharmaceutics. The nanoparticle is composed of a solid lipid component, dihydromyricetin encapsulated in the solid lipid component and a chondroitin sulfate targeting ligand modified on the surface. According to the invention, the chondroitin sulfate is specifically combined with the high-expression CD44 receptor on the surface of the hepatic stellate cell, so that the active targeting delivery of the drug to the hepatic fibrosis focus is realized. The nanoparticles have the characteristics of uniform particle size, high encapsulation efficiency and good slow release effect, can significantly improve the enrichment concentration of dihydromyricetin in the liver, enhance the anti-hepatic fibrosis curative effect and reduce the systemic side effects, and have good application prospects in preparation of hepatic fibrosis targeted therapy drugs.

The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is represented by formula (I). The triptolide lignocerate provided by the present invention is obtained by esterification of triptolide C14-OH and lignoceric acid. The anti-tumor effectiveness, safety and the like of the triptolide lignocerate liposome are further improved with respect to the prior art, so that a foundation is laid for providing safer and more effective triptolide-related clinical preparations.

The invention relates to a pharmaceutical composition for treating or improving intestinal leakage and / or blood-brain barrier injury induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of pseudo-ginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be processed into pharmaceutically acceptable oral dosage forms such as granules, powder and the like; the pharmaceutical composition provided by the invention can improve expression of tight junction protein of vascular endothelial cells and intestinal epithelial cells, reduce the level of blood-brain barrier and intestinal barrier injury markers in blood, improve expression of tight junction protein in blood-brain barrier and intestinal barrier of sleep deprivation patients, reduce influence caused by sleep insufficiency and improve sleep deprivation effect. A new thought is provided for treating the injury problem caused by sleep insufficiency in traditional Chinese medicine.

This invention discloses the application of the Miao medicine Liao's Huafengdan in the preparation of drugs for the prevention and treatment of multiple myeloma, belonging to the field of pharmaceutical application technology. In vitro detection using RPMI8226 and MM1.S multiple myeloma cells revealed that Liao's Huafengdan has a significant inhibitory effect on multiple myeloma. Flow cytometry analysis further showed its effect on cell apoptosis, indicating that Liao's Huafengdan significantly affects apoptosis in multiple myeloma cells, with higher drug concentrations leading to more pronounced apoptosis. Therefore, it can be used as a preparation for the prevention and treatment of multiple myeloma, and can be formulated into pharmaceutically permissible oral liquids, injections, tablets, capsules, and drop pills, providing a new application for Liao's Huafengdan. Moreover, Liao's Huafengdan is already a marketed drug and can be directly applied to humans without further clinical safety assessments, which can rapidly increase the market share of this product.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The invention belongs to the field of pharmaceutics, and particularly relates to a composition containing budesonide and formoterol, and the composition provided by the invention is in a specific pH range, adopts a specific surfactant addition mode, also adopts moist heat sterilization, and is free of toxic and side effects. The prepared inhalation suspension of formoterol and budesonide has better delivery rate and total delivery amount, better fine particle fraction and smaller particle size distribution, has the advantages of low temperature, short time, strong penetrating power, economy, rapidness and the like compared with dry heat sterilization and moist heat sterilization, and is more suitable for industrial mass production.

The application discloses a nano-suspension preparation of juglone, which is mainly prepared from 5-15 parts of juglone and 1-20 parts of a stabilizer by weight. The application also adopts a reverse solvent method-high pressure homogenization method to establish a corresponding preparation method, which is simple in process and can obtain smaller drug particle size, thereby improving the drug bioavailability and enhancing the anti-tumor effect. Therefore, the application prepares a novel traditional Chinese medicine nano-preparation of juglone through the means of pharmacy, effectively improves the solubility and bioavailability of juglone. The in-vitro anti-tumor activity experimental results show that the nano-suspension preparation has significant inhibitory activity on the growth of various tumor cells, can be used for preparing drugs for preventing and treating related tumors, increases the targeting and bioavailability of the drug on tumors, reduces the toxicity, provides a new method and strategy for clinical treatment, and has good market prospect and high social value and economic value.

This invention relates to a pharmaceutical formulation and more particularly to one for Active Pharmaceutical Ingredients (APIs) which are recognised under the Biopharmaceutical Classification System (BCS) as a Class I, III or III drug. In addition to the API, it comprises a combination of gelling agents comprising: a primary gelling agent which is agar and a secondary gelling agent which is an alginate together with at least one cation donator, a preservative, and water and optionally a thickening agent, sweetener(s) and flavouring.

The present disclosure pertains to universal and adoptable cell culture substrates designed for applications in biology, medicine, pharmaceutics, and other relevant fields. The disclosure particularly focuses on processes and methodologies for manufacturing such substrates, which prove advantageous for both non-neural (cells exhibiting robust adhesion and weak cell-cell junctions, as well as cells with regular adhesion and cell-cell junctions) and neural cell sheet engineering. These substrates aim to enhance cell adhesion, stimulate cell growth, and enable rapid and uniform harvesting of cell sheets. Additionally, the present invention introduces a scaffold-free method for tissue engineering, facilitating the creation of a 2D / 3D neural tissue construct featuring unidirectional neuron bundles.

The invention discloses an application of a Yindan Xinnaotong soft capsule in preparation of a medicine for treating type 2 diabetes mellitus, a luciferase reporter gene plasmid is constructed by targeted targeting of a glucagon-like peptide-1 receptor (GLP-1R), which is one of the most effective targets for treating the type 2 diabetes mellitus at the present stage, HEK-293T is used as a tool cell in vitro, and the application of the Yindan Xinnaotong soft capsule in preparation of the medicine for treating the type 2 diabetes mellitus is realized. GLP-1R luciferase reporter gene plasmids are transfected into the GLP-1R promoter, and luciferase reporter gene experiments find that the Yindan Xinnaotong soft capsule can significantly up-regulate the activity of the GLP-1R promoter. Furthermore, verification is carried out through in-vitro and in-vivo experiments, and results show that the Yindan Xinnaotong soft capsule has a certain protection effect on MIN6 cells damaged by palmitic acid and has a remarkable improvement effect on glucolipid metabolism of mice with type 2 diabetes by influencing a GLP-1R signal channel, so that the Yindan Xinnaotong soft capsule can be used as a preparation for treating the type 2 diabetes and has a good application prospect. The traditional Chinese medicine composition can be prepared into oral liquid, injection, tablets, capsules, granules, dripping pills and the like which are permissible in pharmacy.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine, empagliflozin, folic acid substances and a pharmaceutically acceptable carrier, wherein the amlodipine, the empagliflozin and the folic acid substances are in medicinal effective dose. The invention also provides application of the pharmaceutical composition in preparation of medicines for treating lower limb artery occlusion diseases.

The present disclosure relates to the field of pharmaceutics and particularly provides a sustained-release pharmaceutical composition of sivelestat and a preparation method therefor. The pharmaceutical composition included sivelestat and a phospholipid. The present disclosure uses sivelestat, which is poorly soluble in water, as an active ingredient and the phospholipid as a stabilizer. Particles of sivelestat have excellent aerodynamic performance, good stability, a small amount of auxiliary materials, and a simple preparation process. After inhalation, the drug stays in the lungs for a long time and has a good sustained-release effect and a good industrial production prospect.

The invention relates to a method for providing a water-soluble adduct and an ibuprofen adduct, wherein the membrane permeability of the adduct is improved and the classification according to the Biopharmaceutics Classification System is influenced.

The invention discloses a traditional Chinese medicine beverage capable of soothing nerves, helping sleep and regulating emotion and a preparation method thereof, and particularly relates to the field of traditional Chinese medicine pharmaceutics. The beverage realizes sleep aiding through jujuboside, spinosin, eleutheroside, cyclic adenosine monophosphate and the like, regulates emotion through fingered citron lactone, rose volatile oil and the like, and tranquilizes and stabilizes mind by using hericium erinaceus, hawthorn flavone and the like. The preparation method comprises the following steps: carrying out differential pretreatment on raw materials; volatile oil, water-soluble functional components and flavor substances are obtained through circulating percolation extraction, dynamic countercurrent extraction and mild extraction by adopting a stepped directional extraction process; and precisely filtering and clarifying the extracting solution through a ceramic membrane, compounding with aromatic volatile oil, and sterilizing and filling by adopting a 550MPa ultrahigh-pressure cold sterilization technology. The method overcomes the defects of low extraction efficiency and easy loss of active components in the traditional process, realizes efficient synergistic extraction and complete retention of various active components, and has the advantages of fresh taste, stable character, long shelf life and accurate and controllable process parameters.

This invention provides a yin-nourishing and blood-tonifying medicinal composition, its preparation method, and its application, belonging to the technical field of traditional Chinese medicine compositions. The active ingredients of this composition are prepared from the following raw materials in parts by weight: Astragalus membranaceus 2-3 parts, Angelica sinensis 12-18 parts, Crataegus pinnatifida 2-3 parts, Glycyrrhiza uralensis 2-5 parts, Chrysanthemum indicum 5-9 parts, Melon japonica 20-30 parts, Lemon 15-19 parts, Fine corn flour 2-3 parts, and Whole milk powder 40-44 parts, wherein the weight ratio of Angelica sinensis to Astragalus membranaceus is (6-9):1. The composition of this invention can be prepared into various oral preparations using conventional pharmaceutical processes. The preparation process is stable and controllable, suitable for industrial production. This composition possesses the effects of nourishing yin and blood, strengthening the spleen and promoting digestion, is safe with no toxic side effects, and has an excellent taste. It can be used to prepare drugs for treating and improving yin and blood deficiency syndromes, and has good clinical application and industrialization prospects.

The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-β-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating chronic arrhythmia. The traditional Chinese medicine composition is prepared from rhizoma corydalis, rhizoma galangae, radix curcumae, fructus piperis longi, rhizoma zingiberis and cortex cinnamomi, and volatile oil is extracted from the rhizoma galangae, the rhizoma zingiberis and the cortex cinnamomi; decocting rhizoma corydalis, radix curcumae and fructus piperis longi with water to obtain an aqueous extract; and mixing the volatile oil and the water extract, and drying to prepare a solid preparation. According to the preparation method disclosed by the invention, on the basis of inheriting the classic traditional Chinese medicine, modern scientific and technological means are applied, the traditional Chinese medicine pharmacy characteristic theoretical level and the preparation process technology are innovatively developed, and a'three-effect three-small five-convenient '(efficient, quick-acting and long-acting; dosage, toxicity and side effects are small; the modern traditional Chinese medicine preparation which is convenient to take, carry, store, produce and transport meets the requirements and the actual requirements of the age development, and the traditional Chinese medicine composition (the rhizoma zingiberis recens slices) prepared according to the method disclosed by the invention has the advantages of obviously improved curative effect, convenience in carrying, simplicity and rapidness in taking and high patient compliance.

This application relates to the field of traditional Chinese medicine pharmaceutics technology, specifically disclosing a cold-maceration preparation method for fermented medicinal wine. The method includes the following steps: S1, pulverizing a traditional Chinese medicine composition to obtain coarse powder, wherein the composition includes a principal drug array, an assistant drug array, a adjuvant drug array, and a guiding drug array, and the principal drug array is made from raw materials containing the following parts by weight: 8-12 parts artificial musk, 45-55 parts camphor, and 45-55 parts borneol; S2, mixing the coarse powder obtained in S1 with white wine, sealing and soaking to obtain an soaking mixture; S3, opening the seal and stirring the soaking mixture obtained in S2 to obtain fermented medicinal wine. The cold-maceration preparation method for fermented medicinal wine of this application has the unique advantages of a clear distinction between the principal, assistant, adjuvant, and guiding drug layers in the formulation design, synergistic effects, and a preparation process that can fully and stably extract the effective components of each drug array, resulting in a medicinal wine with concentrated and targeted medicinal power, especially suitable for dispelling deep-seated cold pathogens and clearing meridian blockages.

The invention relates to the field of pharmaceutics, and more particularly to a pharmaceutical choline succinate substance for use in the preparation of medicaments. Proposed is a pharmaceutical choline succinate substance containing 0.01-2.00 wt.% of a compound of formula (I). The obtained substance has elevated stability.

The application discloses an anti-fatigue traditional Chinese medicine composition and a preparation method thereof, and contains the following traditional Chinese medicine raw materials in the weight ratio: 8-12 parts of soybean peptide powder, 9-15 parts of rhizoma polygonati, 3-9 parts of ginseng, 6-12 parts of lily, 9-30 parts of astragalus, 6-12 parts of medlar, 10-15 parts of rehmannia, 6-15 parts of jujube, 5-10 parts of semen ziziphi spinosae, 6-15 parts of lotus seed, 11-13 parts of yam, and 6-8 parts of liquorice, and a preparation method thereof is disclosed; after the medicinal materials are extracted, the soybean peptide powder is added to prepare an oral liquid; the medicine has the effects of replenishing energy, benefiting qi and consolidating the root, calming the heart and soothing the nerves, and has a good recovery effect on fatigue; and the traditional Chinese medicine composition is an oral liquid prepared from the above traditional Chinese medicine raw materials in the weight ratio or further including pharmaceutically acceptable adjuvants.

The invention discloses a solid dispersion containing a macrocyclic compound as well as a preparation method and application of the solid dispersion. The solid dispersion comprises a compound shown in a formula I, and / or a stereoisomer and / or a pharmaceutically acceptable salt of the compound, and / or a solvate of the compound, a carrier material and a surfactant. The solid dispersion prepared by adjusting the types and proportions of the carrier material and the surfactant and combining a spray drying method can improve the solubility of the macrocyclic compound under media with different pH conditions and improve the oral bioavailability of the macrocyclic compound in animal bodies.

The present disclosure pertains to the fields of biology and pharmaceutics and relates to a fusion protein comprising a TGF-βRII extracellular region fragment, a pharmaceutical composition thereof, and use thereof. Specifically, the fusion protein of the present disclosure comprises: a first protein functional region targeting an immune checkpoint and a second protein functional region with TGF-β binding activity, wherein the second protein functional region is a variant of a TGF-βRII extracellular region fragment, and the variant of the TGF-βRII extracellular region fragment is: the first serine at the N-terminus of the TGF-βRII extracellular region fragment is replaced with alanine, glycine, or threonine, and / or a fragment comprising the amino acid sequence set forth in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular region fragment. The fusion protein of the present disclosure can simultaneously inhibit TIGIT and reduce TGF-β levels, demonstrating good potential for preparing anti-tumor drugs.

A uric acid-lowering composition includes a pharmaceutically effective ingredient, a pharmaceutically acceptable filler, a flavoring agent, a disintegrant, cross-linked polyvinylpyrrolidone (PVPP), and a lubricant. The pharmaceutically effective ingredient is composed of febuxostat and sodium bicarbonate in a mass ratio of 20-30:1, wherein the sodium bicarbonate is prepared into sodium bicarbonate spray particles by spray granulation after mixing with PVPP. This invention provides a uric acid-lowering pharmaceutical composition that solves the technical problem of low stability and reduced efficacy when sodium bicarbonate and febuxostat are mixed. It is used for the treatment of hyperuricemia, has a rapid onset of action, and can reduce the incidence of adverse digestive system reactions such as acid reflux and gastritis during use. The product disintegrates rapidly, completely within 10 seconds, exhibits good stability, and shows almost no change in product content and related substances during its shelf life, ensuring full efficacy. It is worthy of market promotion and application.

The invention provides an irbesartan solid dispersion and a preparation method of a preparation thereof, and belongs to the technical field of pharmaceutical preparations, the irbesartan solid dispersion is prepared from 10-30% by weight of irbesartan, 60-90% by weight of copovidone and 5-15% by weight of a plasticizer by adopting a twin-screw hot melt extrusion process, and the irbesartan solid dispersion is prepared from the preparation method of the irbesartan solid dispersion and the preparation of the irbesartan solid dispersion. And mixing the solid dispersion with a filling agent, a disintegrating agent and a lubricating agent which are conventional in pharmaceutics to prepare irbesartan unilateral tablets, or additionally adding hydrochlorothiazide and mixing to prepare irbesartan compound tablets. According to the irbesartan tablet and the preparation method thereof, irbesartan is prepared into the solid dispersion and then prepared into the tablet, so that the electrostatic agglomeration of irbesartan is improved to improve the mixing uniformity of the preparation, the dissolution performance of irbesartan is remarkably improved, and the bioavailability of the medicine is improved; therefore, the problems of insufficient subsequent mixing uniformity caused by electrostatic agglomeration in irbesartan preparation preparation and poor dissolution performance and low bioavailability caused by low solubility are effectively solved.

Systems, methods, and devices predict pharmacokinetic parameters following administration of a formulation, such as a medium-chain triglyceride (MCT). The method includes generating training data indicating human metabolism outcomes of the formulation. The training data includes stomach emptying parameters, a digestion rate, an absorption constant, or a conversion rate with a training target variable being ketone concentration or plasma free fatty acid concentration. The method also includes training a physiologically based biopharmaceutics (PBB) model with the training data and using the PBB model to predict, using the patient data, at least one of a target plasma free fatty acid concentration or a target ketone concentration. Furthermore, as part of a parameter sensitivity analysis of the PBB model, the method varies input parameters of the training data against a simulated mean plasma free fatty acid profile or a simulated mean ketone plasma profile.

The utility model provides a novel water quality improver preparation part, which relates to the technical field of water quality improver preparation and comprises a dissolving tank, a reaction tank and a filtering tank, a controller is arranged on the surface of the reaction tank, connecting pipes are arranged on the top surface and the bottom surface of the reaction tank, and the reaction tank is connected with the dissolving tank through the connecting pipes. The reaction tank is connected with the filtering tank through a connecting pipe, an ultrasonic generator is arranged in the dissolving tank, an electric heating wire is arranged on the inner wall of the reaction tank, a temperature sensor is arranged on the surface of the reaction tank, a feeding pipe is arranged on the surface of the reaction tank, a stirring assembly is arranged in the reaction tank, and the dissolving tank, the reaction tank and the filtering tank are communicated through the connecting pipe; the device allows the dissolving tank, the reaction tank and the filtering tank to simultaneously perform three operations of solid dissolution, chemical reaction and filtering in stages, and preparation work is simultaneously performed on an upper layer and a lower layer, so that the continuity of the preparation process is enhanced, the efficiency of medicament production is effectively improved, and the production period is shortened.

The invention relates to the field of pharmaceutics, in particular to a staged extraction and alcohol precipitation combined preparation process of compound honeysuckle granules, which comprises the following steps: slowly distilling honeysuckle and fructus forsythiae at low temperature, collecting volatile oil and first aromatic water in a staged manner based on the concentration of the volatile oil, and performing feedback regulation on distillation pressure and distillation temperature based on the liquid state characteristics of condensate in the process, determining a distillation end point according to the volatile oil concentration and collecting a first extracting solution; mixing qualified first aromatic water based on aromatic water relative density evaluation to obtain second aromatic water; dynamically and circularly extracting scutellaria baicalensis and dregs by using water and second aromatic water, feeding back and adjusting the extraction temperature and the circulating frequency on the basis of impurity state parameters, and collecting a second extracting solution; merging the extracting solutions, performing alcohol precipitation, and performing vacuum concentration to obtain extract; uniformly mixing the segmented volatile oil, the extract, a drying auxiliary agent and a flavoring agent to obtain a soft material; and granulating, drying and finishing to obtain the granules. According to the method, volatile oil recovery, solvent internal circulation, impurity look-ahead inhibition and low-heat taste correction are realized, and the yield consistency is remarkably improved.

The invention relates to the field of pharmaceutics and medicine, namely, to a new dosage form of cortexin, rectal suppositories, capable of normalizing brain functions and characterized by efficacy and safety comparable to an injectable form. The invention also relates to a rectal cortexin composition in a suppository form, the composition comprising cortexin in a pharmacologically effective amount and a suppository base.

The invention belongs to the field of pharmaceutics, and particularly relates to a depot type local anesthetic sustained-release composition as well as a preparation method and application thereof, and the depot type local anesthetic sustained-release composition comprises the following components: a, active pharmaceutical ingredients; b, a slow-release carrier material; c. A phospholipid; d. A pharmaceutically acceptable oil; and e. A pharmaceutically acceptable solvent, the new composition not only can maintain the long-acting slow-release effect of the preparation composition, but also accelerates the corrosion absorption of the preparation composition in the body, on one hand, promotes the complete release of the medicine, on the other hand, accelerates the absorption of the preparation, obviously improves the medication safety and bioavailability, and has the advantages of good slow-release effect, good physical and chemical stability and no toxic or side effect. An in-vivo animal experiment shows that no inflammatory reaction occurs at the administration part, the safety is good, and a wide clinical application prospect is achieved.

The invention discloses a copper liposome capable of targeting breast cancer cell mitochondria and a preparation method and application thereof, and belongs to the field of pharmaceutics, and the copper liposome capable of targeting breast cancer cell mitochondria is (4-carboxybutyl) triphenylphosphonium bromide covalent octadecylamine copper liposome, the copper liposome is a copper liposome modified by (4-carboxybutyl) triphenylphosphonium bromide covalent octadecylamine as a ligand; the structural formula of the (4-carboxybutyl) triphenylphosphonium bromide covalent octadecylamine is shown in the specification. The (4-carboxybutyl) triphenylphosphonium bromide covalent octadecylamine copper liposome disclosed by the invention can be used for realizing accurate targeting of mitochondria and effectively inhibiting tumor cell proliferation in a copper death manner.